Financial Reports and Presentations

Year
 ReportPresentationWebcast
August 22, 2024Interim Report Q2 2024 (in Swedish)
August 22, 2024Interview Carnegie Investment Bank
June 4, 2024Presentation - Penser by Carnegie Healthcare Event
May 23, 2024Interim Report Q1 2024 (in Swedish)
April 23, 2024Annual Report 2023 (in Swedish)
March 26, 2024Live-streamed R&D update regarding Paccal Vet
February 26, 2024Presentation - Vivesto - Fokuserat och slimmat för en nystart
February 22, 2024Year-end Report 2023 (in Swedish)
November 17, 2023Presentation - Vivesto - Paccal Vet redo för nästa steg
November 16, 2023Interim Report Q3 2023
October 26, 2023Interview Erik Penser Bank
August 24, 2023Interim Report Q2 2023
August 24, 2023Presentation - EPB Bolagsdag
May 25, 2023Interim Report Q1 2023
May 25, 2023Presentation Erik Penser Bank
April 25, 2023Annual Report 2022
February 23, 2023Year-end Report 2022
November 17, 2022Interim Report January – September 2022
August 25, 2022Interim Report January – June 2022
May 25, 2022Interim Report January – March 2022
May 5, 2022Anglonordic Life Science Conference
April 28, 2022Annual Report 2021
March 14, 2022Oasmia Pharmaceutical – Aktiedagen Stockholm
January 19, 2022Year-end Report 2021
January 19, 2022Rights Issue Presentation at Erik Penser Bank
December 2, 2021Presentation at Stora Aktiedagen Stockholm
December 2, 2021Oasmia - Presentation Erik Penser Bank
November 18, 2021Interim Report January – September 2021
October 21, 2021Interview Erik Penser Bank
September 29, 2021Naventus LifeScience Summit
September 7, 2021Presentation at Aktiedagen Stockholm
August 19, 2021Interim Report January – June 2021
June 11, 2021Aktiespararna: Interview with Oasmia Pharmaceutical
May 27, 2021Interim Report January – March 2021
April 29, 2021Annual Report 2020
April 12, 2021Cantrixil abstract from Final Phase I Data at the 2021 AACR Annual Meeting
March 21, 2021BioEurope Spring, Virtual
March 11, 2021Sachs 14th Annual European Life Sciences CEO Forum, Virtual
March 1, 2021Oasmia acquires global development and commercialization rights for Cantrixil
February 19, 2021Year-end report 2020
January 19, 2021SEB Digital Healthcare Seminar Presentation
December 9, 2020Interim Report May – October 2020 – Report
December 3, 2020Oasmia’s Partner Elevar Provides an Update on Apealea Development Plans in Ovarian Cancer
November 11, 2020Investival Showcase 11-16 November 2020, Virtual Conference
October 29, 2020BIO-Europe®, Virtual Conference
October 7, 2020Oasmia Erik Penser Cancer Day Presentation
September 24, 2020Oasmia Erik Penser Investor Event Presentation
September 21, 2020Presentation at Sachs Biotech in Europe Forum
September 15, 2020Aktiedagen Digitalt
September 9, 2020Interim Report May – July 2020
August 19, 2020Annual Report 2019 / 2020
July 30, 2020Analysguiden: Interview with Oasmia
June 18, 2020Year-end Report 2019 / 2020
June 10, 2020Company Presentation Aktiespararna
June 3, 2020Avanza Börsdag
May 13, 2020Strategic Review Presentation
March 27, 2020Interim Report May 2019 – January 2020
March 25, 2020Elevar deal
February 14, 2020Oasmia appoints new CEO
December 30, 2019Interim Report May – October 2019
September 26, 2019Interim Report May – July 2019
September 5, 2019Annual Report 2018 / 2019
June 28, 2019Year-end Report 2018 / 2019
March 1, 2019Interim report May 2018 – January 2019
November 20, 2018Interim report May – October 2018
August 31, 2018Interim report May – July 2018
August 24, 2018Annual Report 2017 / 2018
June 7, 2018Year-end Report May 2017 – April 2018
March 2, 2018Interim report May 2017 – January 2018
December 1, 2017Interim report May – October 2017
October 31, 2017US Interim report May – October 2016
September 1, 2017Interim Report May – July 2017
August 24, 2017Annual Report 2016 / 2017
August 2, 2017Registration statement on form F3
June 8, 2017Year-end Report May 2016 – April 2017
April 30, 201720-F Annual Report 2016-05-01 – 2017-04-30
March 2, 2017Interim Report May 2016 – January 2017
December 1, 2016Interim Report May – October 2016
December 1, 2016US Interim report May – October 2016
September 1, 2016Interim Report May 2016 – July 2016
August 25, 2016Annual Report 2015 / 2016
July 29, 2016Updated Registration Statement on Form F1
July 8, 2016Updated Registration Statement on Form F1
July 1, 2016Registration statement and Prospectus on Form F1
July 1, 2016US Interim Report May 2016 – July 2016
June 2, 2016Year-end Report May 2015 – April 2016
April 30, 201620-F Annual Report 2015-05-01 – 2016-04-30
April 1, 2016US Year-end Report May 2015 – April 2016
March 2, 2016Interim Report May 2015 – January 2016
January 1, 2016US Interim Report May 2015 – January 2016
December 2, 2015Interim Report May – October 2015
December 2, 2015US Interim Report May – October 2015
October 1, 2015US Interim Report May – October 2015
September 2, 2015Interim Report May – July 2015
August 20, 2015Annual Report 2014 / 2015
July 7, 2015Updated Registration Statement and Prospectus on Form F1
March 4, 2015Interim Report May 2014 – January 2015
December 3, 2014Interim Report May – October 2014
November 1, 2014Prospectus new share issue November 2014
September 4, 2014Interim Report May-July 2014
August 21, 2014Annual Report 2013 / 2014
June 5, 2014Year-end Report May 2013 – April 2014
March 6, 2014Interim Report May 2013 – January 2014
December 5, 2013Interim Report May – October 2013
September 6, 2013Interim Report May – July 2013
March 1, 2013Interim Report May 2012 – January 2013
December 6, 2012Interim Report May-October 2012
October 25, 2012New share issue Prospectus 2012-10-25
September 6, 2012Interim Report May-July 2012
August 23, 2012Annual Report 2011 / 2012
June 14, 2012Year-end Report May 2011-April 2012
March 8, 2012Interim Report May 2011 – January 2012
December 8, 2011Interim Report May – October 2011
November 1, 2011New share issue Prospectus 2010-11-01
September 8, 2011Interim Report May – July 2011
August 25, 2011Annual Report 2010 / 2011
June 10, 2011Year-end Report May 2010 – April 2011
March 9, 2011Interim Report May 2010 – January 2011
December 9, 2010Interim Report May-October 2010
September 9, 2010Interim Report May – July 2010
August 26, 2010Annual Report 2009 / 2010
June 10, 2010Year-end Report May 2009 – April 2010
June 6, 2010Listing Prospectus OMX 2010-06-17
December 10, 2009Interim Report May 2009-October 2009
September 17, 2009Oasmia Listing Prospectus 2007-09-17
September 10, 2009Interim report May 2009 – July 2009
August 28, 2009Annual Report 2008 / 2009
March 19, 2009Interim report May 2008 – January 2009
December 10, 2008Interim Report May 2008 – October 2008
December 10, 2008Interim Report May 2008 – October 2008
September 16, 2008Interim Report May – July 2008
September 16, 2008Interim Report May – July 2008
August 29, 2008Annual Report 2007 / 2008
June 16, 2008Year-end Report 2007-05-01 – 2008-04-30
June 16, 2008Year-end Report 2007-05-01 – 2008-04-30
March 14, 2008Interim Report May 2007 – January 2008
December 14, 2007Interim Report May – October 2007
September 10, 2007Communiqué from Annual General Meeting 2007-09-10
June 15, 2007Year-end Report 2006-05-01 – 2007-04-30
December 10, 2006Interim Report May – October 2006
August 14, 2006Annual Report 2005 / 2006
September 27, 2005Annual Report 2004 / 2005
October 5, 2024Swiss Nordic Bio